BrainCool AB (publ) – The last exercise period for BrainCool’s warrants, BRAIN TO 1, 2017-2020, starts on Friday, November 20, 2020
As part of BrainCool´s with L1 Capital, BrainCool has distributed free warrants to the company's shareholders to reduce dilution. During the period of November 20 to December 4, 2020, holders of BRAIN TO 1 warrants can exercise the warrants and subscribe for new shares. One (1) BRAIN TO 1 warrant can be exchanged for one (1) share, at a price of 2,77 SEK. After the end of this exercise period, the warrants of series BRAIN TO 1 expire and the holders lose their right to subscribe for shares.
Holders of warrants who have their warrants nominee registered in the custody of a bank or broker shall contact their bank to exercise the warrants for subscription.
For directly registered warrant holders, subscription shall be made by filling in a completed application form and sending it to the issuing institution (Eminova Fondkommission) at the same time as payment is made. The application form and payment must be made to Eminova no later than Friday December 4, 2020, at 15:00. Application form can be ordered from Eminova on info@eminova.se or +46 8 684 211 00.
-Series BRAIN TO 1 warrants have ISIN code SE0010713834.
The terms and conditions of the warrants are published on BrainCool's website:
http://www.braincool.se/nyemission/
For more information
Martin Waleij - CEO
+46 - 733 -93 70 76
E-mail: martin.waleij@braincool.se
About BrainCool AB (publ)
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.